C. novyi for the treatment of solid tumors in humans
US-2016051597-A1 · Feb 25, 2016 · US
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
US12427173B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12427173-B2 |
| Application number | US-201515301163-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2015 |
| Priority date | Mar 31, 2014 |
| Publication date | Sep 30, 2025 |
| Grant date | Sep 30, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The presently disclosed subject matter provides methods and kits for treating solid tumors in a subject by using a combination of anti-CTLA-4 and/or anti-PD-1 antibodies with at least one member of the group consisting of a bacterium, bacterial product, and an immunoregulatory entity. In particular embodiments, the bacteria are toxin-depleted, anaerobic bacteria, such as Clostridium novyi -NT.
First claim
Opening claim text (preview).
That which is claimed: 1. A method for debulking a solid colon tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of a combination of an anti-CTLA-4 antibody, and one or more Clostridium novyi bacterium spores, wherein no additional anti-cancer agent is administered. 2. The method of claim 1 , wherein the Clostridium novyi bacterium spores are toxin-depleted and anaerobic. 3. The method of claim 2 , wherein the Clostridium novyi bacterium spores is Clostridium novyi -NT bacterium spores. 4. The method of claim 2 , wherein part of or all of a toxin gene of a wild-type form of the Clostridium novyi bacterium spores is deleted. 5. The method of claim 2 , wherein the toxicity of the Clostridium novyi bacterium spores is reduced by a factor of at least 2 compared to a corresponding wild-type Clostridium novyi bacterium spores. 6. The method of claim 1 , wherein the Clostridium novyi bacterium spores are administered intravenously or intratumorally. 7. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered by at least one method selected from the group consisting of intravenously, intramuscularly, subcutaneously, and intratumorally. 8. The method of claim 1 , wherein the solid colon tumor is malignant. 9. The method of claim 1 , wherein the subject is human. 10. The method of claim 1 , wherein the subject is a non-human animal.
Assignees
Inventors
Classifications
against the immunoglobulin superfamily · CPC title
characterised by the route of administration · CPC title
comprising antibodies · CPC title
Probiotics · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12427173B2 cover?
- The presently disclosed subject matter provides methods and kits for treating solid tumors in a subject by using a combination of anti-CTLA-4 and/or anti-PD-1 antibodies with at least one member of the group consisting of a bacterium, bacterial product, and an immunoregulatory entity. In particular embodiments, the bacteria are toxin-depleted, anaerobic bacteria, such as Clostridium novyi -NT.
- Who is the assignee on this patent?
- Univ Johns Hopkins, Biomed Valley Discoveries Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K35/74. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).